Contents lists available at ScienceDirect

### Materials Letters

journal homepage: www.elsevier.com/locate/matlet

# Influence of particle size on the adsorption and release of cephalexin encapsulated in mesoporous silica SBA-15



<sup>a</sup> Centro de Investigación y Desarrollo en Ciencias Aplicadas (CINDECA), Facultad de Ciencias Exactas, Universidad Nacional de La Plata – CONICET, Calle 47 N

° 257, B1900AJK La Plata, Argentina

<sup>b</sup> Centro de Investigación y Desarrollo en Ciencia y Tecnología de Materiales (CITEMA), Universidad Tecnológica Nacional, Facultad Regional la Plata, Calle 60

y 124, B1923 Berisso, Argentina

#### ARTICLE INFO

Article history: Received 27 October 2015 Received in revised form 2 May 2016 Accepted 11 June 2016 Available online 13 June 2016

Keywords: Sba-15 Particle size Adsorption Drug delivery Cephalexin

#### 1. Introduction

Ordered mesoporous silicas have unique characteristics such as uniform pore size, high surface area, high mechanical strength and good thermal stability at wide temperature ranges. These properties provide great versatility to those materials for different technological applications, particularly in mass transfer processes such as adsorption and immobilization of substances [1–4].

The use of nanotechnology in medicine and more specifically in drug delivery systems is set to spread rapidly. Several drug delivery systems recently studied propose the use of mesoporous silicas as drug carriers [5–9]. Such studies were intended to prove that these porous materials are capable of releasing a carried bioactive agent at a specific rate. The main aim of these new systems is to facilitate the dosage and duration of the drug effect, in order to cause minimal disturbance to the patient by allowing the reduction of the dosage frequency. The particle size and morphology, as well as the size, volume and geometry of the pores, are all important parameters determining the release rate of the incorporated drug molecules [10–14]. An interesting review about the different types and bioapplications of mesoporous materials indicates that mesostructured silicas can nowadays be considered

\* Corresponding author at: Centro de Investigación y Desarrollo en Ciencias Aplicadas (CINDECA), Facultad de Ciencias Exactas, Universidad Nacional de La Plata – CONICET, Calle 47 N° 257, B1900AJK La Plata, Argentina.

E-mail address: eib@quimica.unlp.edu.ar (E.I. Basaldella).

#### ABSTRACT

Ordered mesoporous silicas with different particle sizes were synthesized and used as drug carrier in controlled delivery systems. Morphological properties of mesoporous supports were modified by changing the stirring rate. Changes in the shape of SBA-15 from fiber-like particles to smaller irregular agglomerates were obtained by reducing the stirring rate. The adsorption and release of cephalexin from those different supports were investigated. Adsorption capacity was found to increase with decreasing particle sizes, and the *in vitro* release experiments indicated a clear increase in the amount released from the smaller particles. *In vivo* studies revealed that silica matrixes effectively control the drug release and were capable of maintaining a sustained therapeutic blood level of cephalexin.

© 2016 Elsevier B.V. All rights reserved.

as one of the most efficient matrices for drug delivery [15].

Long-acting release formulations for subcutaneous administration would be a good therapeutic option when oral administration is restricted (vomiting) or difficult (for fractious animals). In previous work we demonstrated that cephalexin could successfully be loaded on SBA-15 mesoporous silica [16-18]. Cephalexin is a semisynthetic first-generation cephalosporin, with great gram-positive coverage and some activity against gram-negative bacteria, which is indicated for the treatment of various infections, including bone, joint and dental infections [19]. Additionally, the biocompatibility of SBA-15 was analyzed. Previous biopsy results obtained after injection of physiological solution containing SBA-15 particles to a group of rats sacrificed in a CO<sub>2</sub> chamber showed that irritation or inflammation was not detected in the skin [20]. To go further in this research, in this work we evaluate the *in vitro* adsorption and drug release of cephalexin from SBA-15 silicas possessing different particle sizes. Results for in vivo release were also obtained.

#### 2. Experimental

SBA-15 materials were synthesized according to the procedure reported by Zhao et al. [21] by using tetraethylorthosilicate (TEOS; Aldrich) as silica source and Pluronic 123 triblock copolymer (P123, EO20-PO70-EO20; Aldrich) as template. The molar composition used was 1TEOS:4.88HCl:0.0172Pluronic:158.33H<sub>2</sub>O. The





CrossMark

solution was heated up to 35 °C before adding the TEOS. The resulting solution was stirred for 20 h at 35 °C, followed by aging at 80 °C for 24 h under static conditions. The solid product was recovered by filtration and dried at room temperature overnight. The template was removed from the as-made mesoporous material by calcination at 540 °C for 6 h. Different size particles were obtained by modification of the stirring rate (120 and 400 rpm) [22]. The samples were called SBA<sub>120</sub> and SBA<sub>400</sub>.

SEM micrographs were obtained by using a Scanning Electron Microscope Philips 505. Transmission electron microscopy (TEM) was performed with a Leo EM-910 instrument operated at 120 kV. The adsorption-desorption nitrogen isotherms were measured at – 196 °C using Micromeritics apparatus ASAP 2020 (Micromeritics, Atlanta, Georgia). The Brunauer–Emmett–Teller (BET) equation was used to calculate the surface area in the range of relative pressures between 0.05 and 0.20. The pore size distribution was obtained by the BJH method, using the adsorption branch of the loop. The pore volume was taken at the P/P<sub>0</sub>=0.989 single point.

The two SBA-15 samples were soaked in a solution of cephalexin (CPX) in water (concentration 1 mg/mL). The resulting suspensions (1 mg solid/mL liquid) were left at ambient temperature, with stirring for 6 h. The solid phases were separated from the liquids by filtration and dried at room temperature. The respective samples were denoted as  $SBA_{120}$ /cpx and  $SBA_{400}$ /cpx.

For drug release experiments, 0.2 g. of prepared samples (SBA<sub>120</sub>/cpx and SBA<sub>400</sub>/cpx) were put in contact with 1000 mL of simulated body fluid (SBF) [23]. The cephalexin content in the liquid phase was determined by UV–visible spectroscopy at 262 nm (UV-1800 Shimadzu, Japan).

The *in vivo* study was carried out in three healthy New Zealand white rabbits 3.0–3.5 kg in weight. All animal procedures were approved by the Institutional Animal Care and Use Committee, School of Veterinary, University of La Plata, Argentina. Animals received the 10% w/v of SBA<sub>400</sub>/cpx formulation at a dose rate of 60 mg/kg by subcutaneous (SC) injection. Blood samples (0.4 mL) were collected in K-EDTA, through a 24 G x <sup>3</sup>/<sub>4</sub>" intravenous catheter (Introcan<sup>®</sup>, Braun Aß, Germany) placed in the marginal ear vein, at 0.5, 0.75, 1, 6, 12, 24, 48, 72 and 96 h post-administration. Cephalexin plasma concentration was determined by microbiological assay [24]. The limit of detection and quantification of the method were 0.19 and 0.39 µg/mL, respectively. Inter and intra-assay coefficients of variation were 9.39% and 4.87%, respectively.

#### 3. Results and discussion

Fig. 1 shows SEM micrographs of the solids obtained. It can be seen that a high stirring rate (400 rpm) leads to particles with the same size and shape (fiber-like) as conventional SBA-15 reported by Zhao et al. [21]. A decrease in the stirring rate to 120 rpm produces a significant decrease in particle size. According to Zhao et al. [25], highly energetic organic-inorganic interfaces favor fiber formation, whereas systems with low energy lead to morphologies with lower energy and smaller in size. Fig. 2 displays the  $N_2$ sorption isotherms recorded for the obtained silicas. Type IV adsorption isotherms with an H1 hysteresis loop (according to the IUPAC classification) were observed [26]. For the two samples, typical capillary condensation was observed within a relative pressure range of 0.4–0.8, reflecting the presence of mesopores. This result is in good agreement with the related TEM analysis (Fig. S1). The sharpness of the two loops indicates that both silicas have narrow pore size distributions. The partial pressure related to the onset of hysteresis indicates an averaged mesopore diameter that is smaller for SBA<sub>120</sub> (3.5 nm) than for SBA<sub>400</sub> (4.5 nm). Table S.1 summarizes the textural properties of SBA-15 materials prepared with different stirring rates.

The adsorption kinetic curves showed that the equilibrium time for SBA<sub>120</sub> and SBA<sub>400</sub> was 5.5 h and 5 h, respectively (Fig. 3. A). SBA<sub>120</sub> shows higher adsorption capacity of CPX than SBA<sub>400</sub>. This may be attributed to the difference in their particle sizes. Smaller particles increase the probability of access of the CPX molecule to pores of the siliceous matrix. The conventional material presenting larger particle size leads to slower adsorption due not only to the possibility of pore blockage by the cephalexin molecules entering through the silica pore channels, but also to their increased pore length and tortuosity. Therefore, it is unlikely that complete monolayer coverage of the internal surface area could be achieved. Additionally, it has to be noted that SBA<sub>120</sub> presents a smaller pore diameter than SBA<sub>400</sub> (Table S.1), but the cephalexin size (about 1 nm) is by far smaller than the SBA<sub>120</sub> pore size.

*In vitro* CPX release profiles of all drug-loaded materials were linear at the initial drug release stage on the plot. The particle size of the materials affects the adsorption capacity, and also alters the amount of drug released. The SBA<sub>400</sub> support releases a lower amount of cephalexin than the SBA<sub>120</sub> according to the particle size and the decreased tortuosity in diffusional path (Fig. 3. B). The initial drug release from SBA-15 was very rapid, but the release slowed down considerably after 10 h. The total drug released from SBA<sub>120</sub> and SBA<sub>400</sub> was about 85% and 60%, respectively. Adverse



Fig. 1. SEM images of SBA-15 materials obtained at different stirring rates. a) SBA<sub>400</sub>, bar = 2 µm; b) SBA<sub>120</sub>, bar=2 µm.

Download English Version:

## https://daneshyari.com/en/article/1641017

Download Persian Version:

https://daneshyari.com/article/1641017

Daneshyari.com